Archivos espanoles de urologia · 2025
Effect of Sarcopenia on Treatment of Erectile Dysfunction.
СтатьяНаблюдательное исследованиеМногоцентровое исследованиеНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Başer Aykut, Doğan Çağrı, Alkiş Okan, Çeker Gökhan, Akgün Uğur, Bahçeci Tuncer, Görgü Nart, Turunç Tahsin, Gül Umit
Аннотация
BACKGROUND: Erectile dysfunction (ED) and sarcopenia share common risk factors, particularly advanced age. This study aimed to assess the effect of sarcopenia on ED treatment outcomes.
MATERIALS AND METHODS: A prospective observational study was conducted, involving patients receiving ED treatment from six different centres. Sarcopenia was evaluated using the Strength, Assistance with walking, Rise from a chair, Climb stairs and Falls (SARC-F) questionnaire, the 30-Second Chair Stand Test, and the 4-Meter Walk Test. The International Index of Erectile Function (IIEF) questionnaire was used to assess ED severity. The treatment response in patients regularly using phosphodiesterase type 5 inhibitors (PDE5i) for ED was analysed in relation to sarcopenia.
RESULTS: The study included 137 patients (mean age = 54.91 ± 12.46 years) who regularly used PDE5i. Sarcopenia suspicion was present in 15.33% (n = 21) of patients. Those with suspected sarcopenia were older (mean age = 64.62 ± 5.83 years) and had lower baseline IIEF scores (8.76 ± 3.57) than patients without suspected sarcopenia (p < 0.001 for both). Whilst the IIEF scores significantly increased after PDE5i treatment in patients without suspected sarcopenia (from 11.64 ± 4.82 to 17.28 ± 5.70; p < 0.001), the increase was not significant in those with suspected sarcopenia (from 8.76 ± 3.57 to 9.81 ± 5.14; p = 0.283).
CONCLUSIONS: Sarcopenia may contribute to a poor response to ED treatment, particularly in older patients. It could be a significant factor in ED treatment resistance, especially at an advanced age.
MATERIALS AND METHODS: A prospective observational study was conducted, involving patients receiving ED treatment from six different centres. Sarcopenia was evaluated using the Strength, Assistance with walking, Rise from a chair, Climb stairs and Falls (SARC-F) questionnaire, the 30-Second Chair Stand Test, and the 4-Meter Walk Test. The International Index of Erectile Function (IIEF) questionnaire was used to assess ED severity. The treatment response in patients regularly using phosphodiesterase type 5 inhibitors (PDE5i) for ED was analysed in relation to sarcopenia.
RESULTS: The study included 137 patients (mean age = 54.91 ± 12.46 years) who regularly used PDE5i. Sarcopenia suspicion was present in 15.33% (n = 21) of patients. Those with suspected sarcopenia were older (mean age = 64.62 ± 5.83 years) and had lower baseline IIEF scores (8.76 ± 3.57) than patients without suspected sarcopenia (p < 0.001 for both). Whilst the IIEF scores significantly increased after PDE5i treatment in patients without suspected sarcopenia (from 11.64 ± 4.82 to 17.28 ± 5.70; p < 0.001), the increase was not significant in those with suspected sarcopenia (from 8.76 ± 3.57 to 9.81 ± 5.14; p = 0.283).
CONCLUSIONS: Sarcopenia may contribute to a poor response to ED treatment, particularly in older patients. It could be a significant factor in ED treatment resistance, especially at an advanced age.